Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Jiangsu Carephar Pharmaceutical Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This means that each pending matter is being evaluated by a different examiner in a different technical division of the USPTO.
ROSENTHAL, ANDREW S is the busiest examiner for the company, with 1 pending office action. This represents 1 of the total 2 pending office actions. The other action is handled by the second distinct examiner. This lack of overlap in both examiners and art units requires the applicant to manage two separate prosecution tracks.
The involvement of 2 distinct art units for only 2 pending office actions suggests that the company's innovations span different technical classifications. Practitioners must be prepared for varied examination styles and different sets of prior art across these 2 distinct examiners. The 2 pending office actions represent the current active workload for the company's Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18996105 | PHARMACEUTICAL COMPOSITION CONTAINING PYRROLE GASTRIC ACID SECRETION INHIBITOR AND PREPARATION METHOD THEREFOR | ROSENTHAL, ANDREW S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17631596 | JAK KINASE INHIBITOR AND USE THEREOF | ROMERO, KRISTEN WANG | 31d overdue |
| 18996105 | PHARMACEUTICAL COMPOSITION CONTAINING PYRROLE GASTRIC ACID SECRETION INHIBITOR AND PREPARATION METHOD THEREFOR | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18996105 | PHARMACEUTICAL COMPOSITION CONTAINING PYRROLE GASTRIC ACID SECRETION INHIBITOR AND PREPARATION METHOD THEREFOR | ROSENTHAL, ANDREW S | 1613 | §101§112 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 17631596 | JAK KINASE INHIBITOR AND USE THEREOF | ROMERO, KRISTEN WANG | 1624 | §112 | Non-Final OA | 31d overdue | Pending | Jan 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial